KANG IKang Healthcare Group Inc. Sponsored ADR Class A

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding the Sale of iKang Healthcare Group, Inc. in a Going Private Transaction is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased iKang Healthcare Group, Inc. (“iKang” or the “Company”) (NASDAQGS: KANG) stock prior to March 26, 2018.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of iKang to a consortium of entities led by CEO and Chairman Lee Ligang Zhang and Vice Chairman of the Board Boquan He. Under the terms of the transaction, iKang shareholders will receive US$41.20 per Class A or Class C common share and US$20.60 per American depositary share. Mr. Zhang and Mr. Boquan have agreed to tender their shares, representing approximately 25.6% of the Company’s outstanding shares and approximately 43.1% of total voting power of the outstanding shares. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/ikang-healthcare-group-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of iKang breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether the consortium is underpaying for iKang shares, thus unlawfully harming iKang shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
26/03/2018

Underlying

KANGIKang Healthcare Group Inc. Sponsored ADR Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IKang Healthcare Group Inc. Sponsored ADR Class A

 PRESS RELEASE
Free
KANG IKang Healthcar...

iKang Announces Completion of Going Private Transaction

iKang Announces Completion of Going Private Transaction BEIJING, Jan. 18, 2019 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced the completion of its merger (the “Merger”) with IK Healthcare Merger Limited (“Merger Sub”), a wholly owned subsidiary of IK Healthcare Investment Limited (“Parent”), pursuant to the previously announced agreement and plan of merger dated as of March 26, 2018 and amended pursuant to Amendment No. 1 thereto dated as of...

January 18, 2019 1 EN
 PRESS RELEASE
Free
KANG IKang Healthcar...

iKang Announces Unaudited Financial Results for the Fiscal Second Quar...

iKang Announces Unaudited Financial Results for the Fiscal Second Quarter Ended September 30, 2018 BEIJING, Dec. 20, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced its unaudited financial results for the fiscal second quarter ended September 30, 2018. Fiscal Second Quarter Ended September 30, 2018 Financial Highlights Net revenues were US$177.7 million, an increase of 16.6% year-over-year (an increase of 19.0% on RMB basis) (1) Gross p...

December 20, 2018 1 EN
 PRESS RELEASE
Free
KANG IKang Healthcar...

iKang Enters into Amendment No. 3 to Merger Agreement for Going Privat...

iKang Enters into Amendment No. 3 to Merger Agreement for Going Private Transaction BEIJING, Dec. 14, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced that it has entered into an amendment No. 3 (“Amendment No. 3”) to amend its previously announced agreement and plan of merger, dated as of March 26, 2018 and amended pursuant to Amendment No. 1 thereto dated as of May 29, 2018 and Amendment No. 2 thereto dated as of September 25, 2018 (the ...

December 14, 2018 1 EN
 PRESS RELEASE
Free
KANG IKang Healthcar...

iKang Schedules 2018 Unaudited Second Quarter Earnings Release on Dece...

iKang Schedules 2018 Unaudited Second Quarter Earnings Release on December 20, 2018 BEIJING, Dec. 06, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced that it will release its unaudited financial results for the second quarter ended September 30, 2018 on December 20, 2018 after the US market closes. The earnings press release and the earnings powerpoint presentation will be available on the investor relations page at . About iKang Health...

December 6, 2018 1 EN
 PRESS RELEASE
Free
KANG IKang Healthcar...

iKang Healthcare Group, Inc. Extends Shareholder Rights Plan

iKang Healthcare Group, Inc. Extends Shareholder Rights Plan BEIJING, Nov. 29, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), announced today that its board of directors (the “Board of Directors”) has unanimously approved the extension of its Rights Agreement, presently scheduled to expire on December 2, 2018, for another year. The Rights Agreement is designed to ensure that all shareholders of the Company receive fair and equal treatment in the event that an unsolicited attempt is made to acquire the Company outside of the process led ...

November 29, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch